Health
China Sinopharm’s potential COVID-19 vaccine triggers antibodies in clinical trials – CNA
BEIJING: A coronavirus vaccine candidate developed by a unit of China National Pharmaceutical Group (Sinopharm) appeared to be safe and triggered antibody-based immune responses in early and mid-stage trials, researchers said.
BEIJING: A coronavirus vaccine candidate developed by a unit of China National Pharmaceutical Group (Sinopharm) appeared to be safe and triggered antibody-based immune responses in early and mid-stage trials, researchers said.
The potential vaccine has already moved into a late-stage trial, one of a handful of candidates being tested on several thousand people to see if they are effective enough to win regulatory approval.
Advertisement
Advertisement
Sinopharm is testing the potential vaccin…
-
General15 hours agoARIA Awards 2025 winners: Amyl & The Sniffers and Ninajirachi dominate
-
Noosa News24 hours agoChild, 15, arrested over death of another child, 8, after shocking e-bike crash in Queensland
-
Noosa News15 hours agoPolice officer who tracked Toyah Cordingley’s phone gives evidence at Rajwinder Singh’s murder trial
-
Noosa News22 hours agoDeath of German shepherd Arnie prompts Brisbane community action to protect pets caught up in crime